Date: 2026-02-22 Quarter: Q3 FY25 (Sep-25) Market cap: ~$3.2B | P/S (TTM): 3.8x | Revenue growth: 74% YoY Atlas baseline read: Yes — agree on core thesis, adding GR framework overlay
ARX delivered its best quarter yet — $267.4M revenue (+74% YoY, accelerating for 3rd straight quarter), $79.8M adj net income (+320% YoY), and a platform that is clearly working. Take rate expanded, loss ratios improved, pipeline hit $3B. This is a growth stock doing growth stock things. The one complexity: management is deliberately compressing FY26 margins from ~25% to ~5.4% to execute a platform transition. This creates near-term noise that obscures what could be an exceptional business.
I'm initiating coverage. GauchoRico has no prior position.
| Factor | Rating | Assessment |
|---|---|---|
| Growth >40% | PASS | 74% YoY, accelerating from 38.9% → 68.4% → 74.0% |
| Trajectory | UP | 3 consecutive quarters of YoY acceleration. Rare. |
| Gross Margins | N/A / MID | Insurance platform — no traditional GM. EBITDA 25% underlying (heading to 5.4% FY26 by choice). |
| Competitive Advantage | STRONG | 265 members, 57k data attributes (up from 23k), 135% NRR, 15 members removed since 2018. The data moat is real. |
| Valuation | CHEAP | 3.8x P/S at 74% growth. ~8x FY26E EBITDA ($269M guide). Historically traded to 31; currently 15. |
| Special Circumstances | PRESENT | IPO overhang behind them. Deliberate margin compression creating market confusion. Platform transition mispricing. |
| Q124 | Q224 | Q324 | Q424 | Q125 | Q225 | Q325 | |
|---|---|---|---|---|---|---|---|
| Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | |
| Revenue ($m) [Non-GAAP] | 128.1 | 130.1 | 153.7 | 190.7 | 178.0 | 219.1 | 267.4 |
| YoY % | — | — | — | — | 38.9% | 68.4% | 74.0% |
| QoQ % | — | +1.6% | +18.1% | +24.1% | -6.7% | +23.1% | +22.0% |
| EBITDA ($m) [Adj] | 27.5 | 13.0 | 26.1 | 46.4 | 42.8 | 63.5 | 105.0 |
| EBITDA Margin % [Adj] | 21.5% | 10.0% | 17.0% | 24.3% | 24.0% | 29.0% | 39.3%* |
| Adj Net Income ($m) | — | — | 19.0 | — | — | 28.6 | 79.8 |
| Adj EPS [Non-GAAP] | — | — | ~$0.10 | — | — | ~$0.15 | $0.38 |
| EWP ($m) | 551 | 727 | 796 | 833 | 874 | 911 | 1,043 |
| EWP YoY % | — | — | — | — | 58.5% | 25.3% | 31.0% |
| Members | 170 | 186 | 204 | 217 | 232 | 248 | 265 |
| Gross Loss Ratio % | 52.1% | 54.7% | 51.8% | — | 53.3% | 50.5% | 50.1% |
| NRR % | — | — | (146%) | — | — | 151% | 135% |
| Take Rate % | — | — | — | — | — | 7.1% | 8.0% |
*Q3 EBITDA includes $39M non-recurring investment gain. Underlying operational EBITDA = $66M (24.7% margin).
Three consecutive quarters of accelerating YoY growth is not common. Most companies in this size range see deceleration as law of large numbers kicks in. ARX went 38.9% → 68.4% → 74.0%. And critically, the driver is not just more members — it's revenue per member expanding. Take rate moved from 7.1% to 8.0% in one quarter. That's pricing power. That's what a platform does when it has leverage.
The QoQ pattern is worth noting: Q1 FY25 was seasonally soft (-6.7%) as expected for a Q1, then +23.1% in Q2, +22.0% in Q3. The underlying momentum is strong.
Let me be direct about this because it's the crux of the investment case.
FY26 guided EBITDA margin: 5.4%. That is not a typo. On $5B+ EWP, management is guiding $269M adj EBITDA = 5.4%. Today's underlying margin is ~25%. Why?
Because Accelerant is deliberately shifting volume from its own Hadron risk-retention vehicle (where it bears underwriting risk and earns ~25% margins) toward third-party insurers (where it earns exchange fees/ceding commissions with lower margin but no underwriting risk). This is the right long-term strategic move — it creates a capital-light, scalable platform rather than a leveraged insurance company. But in the near term, it compresses reported margins significantly.
The question I'm asking: is this the same as a SaaS company investing in sales headcount that compresses margins temporarily before operating leverage kicks in? Or is the 5.4% the new normal?
Management's 3-5 year target of 67% third-party mix (from 32% today) suggests they expect to get there gradually. If take rates hold or expand, and third-party volume scales, the absolute EBITDA dollars grow even if margin % is lower. I can live with 5% margins on $10B EWP = $500M EBITDA. I cannot live with 5% margins being the ceiling.
At this point: I don't know the answer. Seven quarters of public data is not enough to stress-test management's long-term margin model. This is the key risk.
EWP QoQ acceleration: Q3 was +14.4% QoQ — the strongest sequential quarter since Q2 FY24. The $3B pipeline with $1.8B already under contract is a new disclosure and a strong indicator for FY26. I'll be watching whether Q1 FY26 EWP comes in at $1.25B+ quarterly pace to validate the $5B target.
NRR: 135% is strong, declining is a watch item. The prior print was 151%; this quarter is 135%. Still top-quartile (anything above 120% is exceptional). But directionally: 146% → 151% → 135% is a mixed picture. If NRR drops below 120%, that tells me existing members are not expanding as expected and the organic growth engine is weakening. I'm watching this metric closely.
Take rate expansion (7.1% → 8.0%): This is a bullish data point that the market is undervaluing. As the exchange grows, Accelerant has pricing power. An 8% take rate on $5B EWP = $400M in exchange services revenue alone. That alone would justify today's valuation.
Gross loss ratio (50.1%, improving): Underwriting quality is holding up. The 95%-under-$10K policy concentration is insulating the book from the industry-wide liability trends hammering competitors. This structural difference is real and durable.
The QoQ EWP deceleration from +14.4% to +3.6% is significant but not alarming — Q4 appears to have seasonal patterns and likely integration work with newly onboarded insurers. The margin drop is more concerning at face value but explained: the $39M investment gain disappears, plus incremental third-party insurer volume at lower margins.
The deceleration in premium growth guidance (from 61% to 28%) is what the market is wrestling with. This is not a 40%+ grower in FY26 by the premium metric. Revenue growth rate could look different if take rates expand and exchange services revenue grows faster than EWP — but we don't have that guidance.
Verdict on guidance quality: Management is being conservative and transparent. The deliberate disclosure of the margin compression trade-off is a sign of honesty. They could have guided higher margins and disappointed later. They chose to set expectations low. I respect that.
At current market cap ~3.2B(stock 15/share post-recovery from $10.50):
| Metric | Value | Assessment |
|---|---|---|
| P/S (TTM ~$855M rev) | 3.7x | Cheap for 74% grower |
| P/S (FY26E ~$1.1-1.2B rev est.) | 2.7-2.9x | Very cheap |
| EV/FY26E EBITDA ($269M) | ~12x | Fair for insurer; cheap for platform |
| Adj P/E (FY26E) | ~20-25x | Reasonable |
Even after recovering from 10.50to 15, ARX is not expensive for what it delivers. The stock would need to get to $25-30 to look fair-valued relative to the growth rate. Analyst consensus at $19-21 is the near-term target. My own DCF: if this platform reaches $10B+ EWP with 10-15% EBITDA margins in 5 years, the equity is worth multiples of today's price.
CRM Benchmark: CRM maintained 20%+ FCF margins throughout its growth phase and compounded for 60 quarters. ARX's trajectory suggests a similar pattern is possible — but FCF data is not yet available and the insurance business model is materially different. I would not draw a direct comparison yet.
Radke on data moat: "Attracting the best MGAs and making them better with our data." The expansion from 23k to 57k unique data attributes in one year is exceptional. This is the moat. More data → better risk scoring → better member performance → more attractive platform for capital providers.
Schiller on organic growth: "Existing members typically represent 80% of our growth." This is what I want to hear. Platform businesses that grow 80% from existing customers are durable. New members are gravy.
Green on operating leverage: Exchange Services revenue of $85M grew 34% YoY; take rate 7.1% → 8.0%. He called it "consistent operating leverage improvement." I believe him — the take rate expansion proves it.
The $3B pipeline disclosure: This is new. Management disclosed $3B annualized in the pipeline with $1.8B already under contract. This was not in prior quarters. This is a forward-looking confidence signal. If correct, FY26 $5B EWP is conservative, not ambitious.
Prior Beliefs: No prior GauchoRico coverage of ARX. Starting fresh.
Initial Beliefs (establishing baseline):
Initiating with small position. The growth rate qualifies (74% YoY, accelerating). The competitive position is real (data moat, 135% NRR, improving loss ratios). The valuation is attractive (3.7x TTM sales).
Position size: 2-3% initially. This is not a top-10 allocation — not enough track record, margin compression is a real near-term headwind, and I need to see Q1 FY26 results before adding conviction. If Q1 FY26 EWP comes in at $1.25B+ and management delivers on the pipeline conversion, I would consider doubling the position.
The bet is: the market is misreading deliberate strategic margin compression as fundamental deterioration. If Q1 FY26 proves the platform model is executing, the stock re-rates.
Watch for: NRR trajectory (must stay above 120%); FY26 Q1 EWP vs. $1.25B implied quarterly pace; any signal that take rates are stable or expanding; employee retention/leadership quality (Glassdoor 3.3/5 is a yellow flag).
We will see what happens...
GR
First GauchoRico analysis of ARX. No prior position. Initiating coverage. Atlas baseline reviewed — agree on core thesis and conviction 3.5. Adding GR framework and action decision.